Test of Discomfort and Malaise of Two Different Urine Catheters in Healthy Volunteers

October 4, 2011 updated by: Coloplast A/S

Comparative Study of Two Different Urine Catheters.

The purpose of this study is to evaluate the safety of a new developed catheter in comparison with an catheter on the market. The study is randomised.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Intermittent catheterization is the preferred method for emptying the bladder in patients with spinal cord injury and neurogenic bladder dysfunction.

Coloplast has developed a new intermittent catheter. In this investigation this new test catheter will be compared with SpeediCath by assessing discomfort and pain associated with catheterization of healthy men. The reason for choosing healthy men is that many catheter users do not have full feeling in their urethra and therefore can not assess the discomfort.

Healthy men who are ≥ 18 years and have no signs of urinary tract infection and do not have abnormalities, disease or have had operational interventions in the urinary tract will be included. They are recruited through advertisements on the website www.forsoegsperson.dk.

Study Type

Interventional

Enrollment (Actual)

41

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Copenhagen, Denmark, 2100
        • Rigshospitalet, dep. 2112

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • 18 years or older
  • Male
  • signed informed Consent,
  • Neg. urine multistix

Exclusion Criteria:

  • Abnormalities,
  • diseases or surgical procedures performed in the lower urinary-tract

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Monza
nonCE marked intermittent catheter
Device: Intermittent catheter CP063CC
intermittent catheterisation
Other Names:
  • Intermittent catheter,
Active Comparator: control
SpeediCath coated catheter
Device: Intermittent catheter CP063CC
intermittent catheterisation
Other Names:
  • Intermittent catheter,
Device: SpeediCath
intermittent catheterisation
Other Names:
  • Intermittent catheter

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Discomfort Measured on the Visual Analog Scale (VAS)
Time Frame: 10 minutes after each catheterisation at visit 1 and at visit 2 which is 5-25 days after visit 1
Outcome measured on a 10 cm Visual Analog Scale ranging from "no discomfort" (0cm) to "worst thinkable discomfort" (10cm).
10 minutes after each catheterisation at visit 1 and at visit 2 which is 5-25 days after visit 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Irritation During Voiding After Catheterization
Time Frame: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1

After each catheterization subjects were asked if they felt any irritation during voiding with answer option yes or no.

Yes - they experienced irritation. No - they did not experience irritation.
10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
Ease of Use Measured on a 5 Point Scale: Insertion Effort
Time Frame: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1

After each catheterization the nurse who conducted the catheterization answered how the catheter insertion had been.

There were 5 answer categories: very difficult - difficult - neither easy nor difficult - easy - very easy
10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
Ease of Use Measured on a 5 Point Scale: Withdrawal Effort
Time Frame: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1

After each catheterization the nurse who conducted the catheterization answered how the catheter withdrawal had been.

There were 5 answer categories: very difficult - difficult - neither easy nor difficult - easy - very easy
10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
Visible Blood
Time Frame: 10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1

Visual blood observed on the catheter or in the urine in connection to catheterization.

The nurse who conducted the catheterization could answer yes or no as follows:

Yes = visible blood observed. No = no visible blood observed.
10 minutes after each catheterization at visit 1 and at visit 2, which is 5-25 days after visit 1
Haematuria
Time Frame: 2 hours after catheterisation at visits 1 and 2

Negative or positive result on a multistix urin analysis.

Negative haematuria: 10 erythrocytes/microliter or less. Positive haematuria: above 10 erythrocytes/microliter.
2 hours after catheterisation at visits 1 and 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Coloplast A/S

Investigators

  • Study Director: Rikke Otttesen, CTM, Coloplast A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (Actual)

May 1, 2010

Study Completion (Actual)

May 1, 2010

Study Registration Dates

First Submitted

May 4, 2010

First Submitted That Met QC Criteria

June 10, 2010

First Posted (Estimate)

June 11, 2010

Study Record Updates

Last Update Posted (Estimate)

October 7, 2011

Last Update Submitted That Met QC Criteria

October 4, 2011

Last Verified

October 1, 2011

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CP063CC

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe